1.Clinical Significance of Decreased Serum IgA Levels in IgG4-Related Disease
Xia ZHANG ; Yuetong XU ; Difei LIAN ; Zhihui WANG ; Hang ZHOU ; Fan YANG ; Yanying LIU
JOURNAL OF RARE DISEASES 2026;5(3):292-302
To explore the clinical significance of decreased serum immunoglobulin (Ig) A levels in patients with IgG4-related disease (IgG4-RD). A retrospective analysis was performed on patients with IgG4-RD hospitalized at Beijing Friendship Hospital, Capital Medical University from January 2012 to December 2024. Patients were divided into three groups according to serum IgA levels: decreased IgA group (< 70 mg/dL), normal group (70-400 mg/dL), and elevated group (> 400 mg/dL), with the decreased IgA group set as the main research subject. Clinical data were collected to compare clinical characteristics and organ involvement among the three groups, and the correlations between IgA levels and various clinical indicators were analyzed. To further verify the robustness of the results, propensity score matching(PSM) with a 1∶2 matching ratio was performed between the decreased IgA group and the normal IgA group for sensitivity analysis. Meanwhile, principal component analysis (PCA) was used to evaluate the overall distribution differences in clinical characteristics among the three groups with different IgA levels. A total of 330 patients with IgG4-RD were included, including 14 in the decreased IgA group, 297 in the normal IgA group, and 19 in the elevated IgA group. The decreased IgA group had a significantly longer median disease course than the normal IgA group and the elevated IgA group (all Decreased IgA level represents a distinct immune subtype of IgG4-RD, with distinct immunological features (elevated IgG/IgG4 levels, reduced C4 level, and increased EOS count), independent of age, gender and disease course. These findings suggest that serum IgA level has potential value for immune typing of IgG4-RD.
2.The Impact of WeiDiao No.3 Formula on the Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer of Lung-Spleen Qi Deficiency Type:A Retrospective Cohort Study
Liming ZHU ; Yuetong XIA ; Xiaona HUANG ; Jiayao XU ; Chunhui JIN
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(12):1647-1656
OBJECTIVE To observe the effect of the Chinese herbal compound Weidiao No.3 Formula(WD-3)combined with immunotherapy and chemotherapy on survival outcomes in patients with advanced non-small cell lung cancer(NSCLC)with lung-spleen qi dificiency type.METHODS A total of 216 patients with stage Ⅲb-Ⅳ NSCLC without driver gene mutations and with lung-spleen qi vacuity pattern and admitted to the oncology departments of Wuxi Hospital of Traditional Chinese Medicine and Jiangnan Uni-versity Affiliated Hospital between January 1,2020,and March 1,2025,were enrolled.Based on whether they received WD-3 oral treatment(≥3 months),they were divided into a Chinese medicine exposure group(n=98;WD-3+immunotherapy combined with chemo-therapy)and a non-exposure group(n=118;immunotherapy combined with chemotherapy alone).Propensity score matching(PSM)was used to balance baseline characteristics.Overall survival(OS),progression-free survival(PFS),and baseline characteristics were com-pared between the two groups.Cox proportional hazards regression model was used to analyze the association between exposure and outcome,and sensitivity analysis was performed.RESULTS After PSM,there were no statistically significant differences in baseline characteristics between the two groups(P>0.05).After matching,the median OS(32.92 months)and median PFS(9.07 months)in the Chinese medicine exposure group were longer than those in the non-exposure group(23.24 months and 7.89 months,respectively),with statistically significant differences(P<0.05).Multivariate analysis was conducted,incorporating age,PD-L1 expression,KPS score,pathological type,and other factors as covariates to assess the independent association between WD3 exposure and OS and PFS outcomes.The results indicated that WD3 exposure was statistically significant in reducing the risk of death(OS outcome)and disease progression(PFS outcome).Specifically,for the OS outcome,the HR was 0.626,with a 95%CI of 0.438 to 0.894,and P=0.01;for the PFS outcome,the HR was 0.721,with a 95%CI of 0.535 to 0.972,and P=0.032.Sensitivity analysis showed robust results(E-value>2.1).CONCLUSION WD-3 combined with immunotherapy and chemotherapy may prolong OS and PFS and reduce mortality risk in patients with advanced NSCLC without driver gene mutations and with lung-spleen qi dificiency type,achieves adequate therapeutic effects.
3.The Impact of WeiDiao No.3 Formula on the Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer of Lung-Spleen Qi Deficiency Type:A Retrospective Cohort Study
Liming ZHU ; Yuetong XIA ; Xiaona HUANG ; Jiayao XU ; Chunhui JIN
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(12):1647-1656
OBJECTIVE To observe the effect of the Chinese herbal compound Weidiao No.3 Formula(WD-3)combined with immunotherapy and chemotherapy on survival outcomes in patients with advanced non-small cell lung cancer(NSCLC)with lung-spleen qi dificiency type.METHODS A total of 216 patients with stage Ⅲb-Ⅳ NSCLC without driver gene mutations and with lung-spleen qi vacuity pattern and admitted to the oncology departments of Wuxi Hospital of Traditional Chinese Medicine and Jiangnan Uni-versity Affiliated Hospital between January 1,2020,and March 1,2025,were enrolled.Based on whether they received WD-3 oral treatment(≥3 months),they were divided into a Chinese medicine exposure group(n=98;WD-3+immunotherapy combined with chemo-therapy)and a non-exposure group(n=118;immunotherapy combined with chemotherapy alone).Propensity score matching(PSM)was used to balance baseline characteristics.Overall survival(OS),progression-free survival(PFS),and baseline characteristics were com-pared between the two groups.Cox proportional hazards regression model was used to analyze the association between exposure and outcome,and sensitivity analysis was performed.RESULTS After PSM,there were no statistically significant differences in baseline characteristics between the two groups(P>0.05).After matching,the median OS(32.92 months)and median PFS(9.07 months)in the Chinese medicine exposure group were longer than those in the non-exposure group(23.24 months and 7.89 months,respectively),with statistically significant differences(P<0.05).Multivariate analysis was conducted,incorporating age,PD-L1 expression,KPS score,pathological type,and other factors as covariates to assess the independent association between WD3 exposure and OS and PFS outcomes.The results indicated that WD3 exposure was statistically significant in reducing the risk of death(OS outcome)and disease progression(PFS outcome).Specifically,for the OS outcome,the HR was 0.626,with a 95%CI of 0.438 to 0.894,and P=0.01;for the PFS outcome,the HR was 0.721,with a 95%CI of 0.535 to 0.972,and P=0.032.Sensitivity analysis showed robust results(E-value>2.1).CONCLUSION WD-3 combined with immunotherapy and chemotherapy may prolong OS and PFS and reduce mortality risk in patients with advanced NSCLC without driver gene mutations and with lung-spleen qi dificiency type,achieves adequate therapeutic effects.
Result Analysis
Print
Save
E-mail